Senate Moves to Keep Politics Out of Cancer Research Funding
oncodaily - On August 2, 2026, US senators introduced a bipartisan temporary spending bill aimed at keeping the federal government funded. The bill also included a provision that would pause earlier proposed […]
AI Summary: Lawmakers advanced a bipartisan measure designed to delay a controversial OMB grantmaking rule and protect peer‑reviewed cancer research funding from politicized oversight. Scientific groups welcomed the move as a pragmatic step to preserve grant integrity and ensure researchers can continue work without sudden administrative disruptions.
- Clinical leaders defend peer review, oppose politicized funding (3)
- Inclusion and funding roles shaping cancer clinical research (3)
- Senate stalls OMB rule to shield cancer grants (3)
Clinical leaders defend peer review, oppose politicized funding
Inclusion and funding roles shaping cancer clinical research
Senate stalls OMB rule to shield cancer grants
Senate Confirms Dr. Erica Schwartz as C.D.C. Director
Apoorva Mandavilli / nytimes - Dr. Schwartz, a deputy surgeon general in the first Trump administration, has publicly supported childhood vaccines.
AI Summary: Senate confirmed Dr. Erica Schwartz as director of the Centers for Disease Control and Prevention after a high-profile nomination process. She will assume leadership of the agency responsible for national disease prevention and public health preparedness, steering CDC policy and operations amid ongoing public‑health challenges and scrutiny of federal responses.
New bipartisan 340B reform bill curbs HHS' rebate pilot
fiercehealthcare - The SUSTAIN 340B Act introduced Wednesday would bring hospital-backed changes, like a clearinghouse to handle improper discounts, and codifies longstanding grey areas in the contentious subsidy program.
AI Summary: Bipartisan lawmakers introduced legislation to rein in HHS’s controversial 340B rebate pilot, pushing back on administrative changes that providers say threaten safety‑net funding. The bill aims to pause or limit the pilot while stakeholders debate drug‑pricing impacts, reimbursements and patient access — the predictable Washington policy scrum.